Literature DB >> 31707330

Income level and inequality as complement to geographical differences in cardiovascular trials.

João Pedro Ferreira1, Patrick Rossignol2, Pooja Dewan3, Zohra Lamiral2, William B White4, Bertram Pitt5, John J V McMurray3, Faiez Zannad6.   

Abstract

BACKGROUND: Analyses of country or regional differences in cardiovascular (CV) trials are based on geographical subgroup analyses. However, apart from map location and related racial, ethnic, and genetic variations, identified differences may also depend on social structure and provision and access to health care, for which country income and income inequality are indicators. The aim of the study was to examine the association between country per capita income and income inequality and prognosis in patients with heart failure or an acute coronary syndrome in 3 international trials (EMPHASIS-HF, EPHESUS, and EXAMINE).
METHODS: Countries were classified into high income or low-middle income (LMICs) and into low, middle, or high inequality using the Gini index. The main outcome measures were all-cause and CV death.
RESULTS: Patients from LMICs and countries with higher inequality were younger, were less often white, had fewer comorbid conditions, and were less often treated with guideline-recommended therapies, including devices. These patients had higher adjusted mortality rates (+15% to +70%) compared with patients from high-income countries and countries with less inequality. Patients from countries with the combination of greater inequality and low-middle income had particularly high mortality rates (+80% to +190%) compared with those that did not have both characteristics. Living in a country that is poor and has inequality had more impact on death rates than any comorbidity. These findings were reproduced in 3 trials.
CONCLUSIONS: Patients from LMICs and countries with greater inequality had the highest mortality rates. The prognostic impact of income and inequality is substantial and should be considered when looking into subgroup differences in CV trials.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31707330     DOI: 10.1016/j.ahj.2019.08.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Association between Atrioventricular Block and Mortality in Primary Care Patients: The CODE Study.

Authors:  Gabriela Miana de Mattos Paixão; Emilly M Lima; André B Quadros; Daniel P R Cabral; Renato R Coelho; Derick M Oliveira; Jamil de Souza Nascimento; Paulo R Gomes; Antonio L Ribeiro
Journal:  Arq Bras Cardiol       Date:  2022-07-18       Impact factor: 2.667

2.  Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000-20.

Authors:  Jie Wei Zhu; NhatChinh Le; Sunny Wei; Liesl Zühlke; Renato D Lopes; Faiez Zannad; Harriette G C Van Spall
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-09-05

3.  Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.

Authors:  Priya Vart; Ricardo Correa-Rotter; Fan Fan Hou; Niels Jongs; Glenn M Chertow; Anna Maria Langkilde; John J V McMurray; Peter Rossing; C David Sjöström; Bergur V Stefansson; Robert D Toto; Walter Douthat; Elizabeth Escudero; Rey Isidto; Dinesh Khullar; Harpreet S Bajaj; David C Wheeler; Hiddo J L Heerspink
Journal:  Kidney Int Rep       Date:  2022-02-02

4.  Acute myocardial infarction and acute heart failure in the Middle East and North Africa: Study design and pilot phase study results from the PEACE MENA registry.

Authors:  Khalid F Alhabib; Habib Gamra; Wael Almahmeed; Ayman Hammoudeh; Salim Benkheddah; Mohammad Al Jarallah; Ahmed Al-Motarreb; Mothanna Alquraishi; Mohamed Sobhy; Magdi G Yousif; Fahad Alkindi; Nadia Fellat; Mohammad I Amin; Muhammad Ali; Ayman Al Saleh; Anhar Ullah; Faiez Zannad
Journal:  PLoS One       Date:  2020-07-22       Impact factor: 3.240

5.  Clinical phenotypes, aetiologies, management, and mortality in acute heart failure: a single-institution study in Latin-America.

Authors:  Héctor González-Pacheco; Amada Álvarez-Sangabriel; Carlos Martínez-Sánchez; José L Briseño-Cruz; Alfredo Altamirano-Castillo; Salvador Mendoza-García; Daniel Manzur-Sandoval; Luis M Amezcua-Guerra; Julio Sandoval; Rafael Bojalil; Diego Araiza-Garaygordobil; Daniel Sierra-Lara; Carlos A Guiza-Sánchez; Rodrigo Gopar-Nieto; Camelia Cruz-Rodríguez; José J Valdivia-Nuño; Brandon Salas-Teles; Alexandra Arias-Mendoza
Journal:  ESC Heart Fail       Date:  2020-11-11

6.  Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

Authors:  Carolyn S P Lam; João Pedro Ferreira; Egon Pfarr; David Sim; Hiroyuki Tsutsui; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Naveed Sattar; Subodh Verma; Martina Brueckmann; Janet Schnee; Daniel Cotton; Faiez Zannad; Milton Packer
Journal:  Eur Heart J       Date:  2021-11-14       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.